| A low-interventional study to evaluate long-term effectiveness of real-world prophylactic treatment with efanesoctocog alfa on joint health in people with haemophilia A (ALTITUDE) |
Ongoing |
Efanesoctocog alfa |
4 |
BIVV001005 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4- related disease |
Ongoing |
Rilzabrutinib |
3 |
EFC17359 |
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| Immune Ablation Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation for The Treatment of Multiple Sclerosis: A Single-Arm Study |
Ongoing |
Busulfan BOS / Cyclophosphamide/ Thymoglobulin |
2 |
2251066 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR) |
Ongoing |
Vericiguat |
2 |
NCT0571408 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency (Harmony) |
Ongoing |
Pegtibatinase |
3 |
TVTX-TVT058-301 |
King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Riyadh) |
| DOMAIN Study: A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients with Diffuse Large B-Cell Lymphoma in the MEA Region. |
Ongoing |
Acalabrutinib |
4 |
D8220R0008 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Specialist Hospital (Dammam) |
| Real-World Effectiveness and Safety Outcomes in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC) Treated With Sacituzumab Govitecan in Second Line and Beyond in Kingdom of Saudi Arabia. |
Ongoing |
Sacituzumab Govitecan |
4 |
GS-AE-979 |
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Specialist Hospital (Dammam) |
| A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis. |
Ongoing |
Frexalimab (SAR441344) |
3 |
EFC17504 |
King Saud University Medical City (Riyadh) |
| A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease (EASi-PROTKT™) |
Ongoing |
Vicadrostat (BI 690517) / Empagliflozin |
3 |
1378-0041 |
Imam Abdulrahman University Hospital (Dammam) , King Abdulaziz University Hospital (Jeddah) , King Faisal Specialist Hospital and Research Center (Riyadh) , King Saud University Medical City (Riyadh) |
| A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. |
Ongoing |
SAR445229 (Amlitelimab) |
3 |
LTS17367 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
